|Other Names||Protein ENL, YEATS domain-containing protein 1, MLLT1, ENL, LTG19, YEATS1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6188a was selected from the C-term region of human MLLT1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Synonyms||ENL, LTG19, YEATS1|
|Function||Component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Chromosome band 11q23 is the site of translocations in myeloid and lymphoid acute leukemias, pediatric leukemias, and treatment-induced secondary acute myelogenous leukemia. The translocation breakpoints cluster in a restricted region of the HRX gene resulting in chimeric genes that encode an N-terminal portion of Hrx fused to various partner proteins. Myeloid/lymphoid or mixed-lineage leukemia translocated to 1 (MLLT1) is a nuclear protein with transcriptional transactivation properties that is fused to Hrx in t(11;19) leukemias. The minimal MLLT1 sequence required for transcription activation was narrowed to the C-terminal 90 amino acids.
Nie, Z., et al., Mol. Cell. Biol. 23(8):2942-2952 (2003).Lavau, C., et al., Proc. Natl. Acad. Sci. U.S.A. 97(20):10984-10989 (2000).Thirman, M.J., et al., Proc. Natl. Acad. Sci. U.S.A. 91(25):12110-12114 (1994).Rubnitz, J.E., et al., Blood 84(6):1747-1752 (1994).Yamamoto, K., et al., Oncogene 8(10):2617-2625 (1993).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.